izpis_h1_title_alt

Deuterated drugs and biomarkers in the COVID-19 pandemic
ID Jansen-van Vuuren, Ross D. (Avtor), ID Jedlovčnik, Luka (Avtor), ID Košmrlj, Janez (Avtor), ID Massey, Thomas E. (Avtor), ID Derdau, Volker (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (3,59 MB)
MD5: F23C1C6747856A5B6139D594A055AB73
URLURL - Izvorni URL, za dostop obiščite https://pubs.acs.org/doi/10.1021/acsomega.2c04160 Povezava se odpre v novem oknu

Izvleček
Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these compounds (if known), and a brief analysis of each study.

Jezik:Angleški jezik
Ključne besede:COVID-19, hydrogen isotopes, inhibitors, metabolism, pharmaceuticals
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:FKKT - Fakulteta za kemijo in kemijsko tehnologijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2022
Št. strani:Str. 41840-41858
Številčenje:Vol. 7, iss. 46
PID:20.500.12556/RUL-144314 Povezava se odpre v novem oknu
UDK:547.8:546.11
ISSN pri članku:2470-1343
DOI:10.1021/acsomega.2c04160 Povezava se odpre v novem oknu
COBISS.SI-ID:131181827 Povezava se odpre v novem oknu
Datum objave v RUL:14.02.2023
Število ogledov:591
Število prenosov:446
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:ACS omega
Skrajšan naslov:ACS omega
Založnik:American Chemical Society
ISSN:2470-1343
COBISS.SI-ID:525873945 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:COVID-19, izotopi vodika, inhibitorji, presnova, zdravila

Projekti

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Queen’s University, Rapid Response Funding

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Southeastern Ontario Academic Medical Organization

Financer:EC - European Commission
Program financ.:H2020
Številka projekta:945380
Naslov:EUTOPIA-Science and Innovation Fellowships
Akronim:EUTOPIA-SIF

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P1-0230
Naslov:Organska kemija: sinteza, struktura in aplikacija

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj